gap junction protein beta 7Genealiases: CX25 · bA136M9.1 · connexin25
Q-omics provides the consensus-scored GJB7 profile across patient tissues and cancer cell-line models. GJB7 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, GJB7 is differentially expressed in 9, with the highest sampling consensus in BLCA. Additionally, GJB7 RNA expression shows 16,865 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight READ, BLCA, and THYM as cancer lineages where GJB7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GJB7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GJB7 survival associations across molecular data types. GJB7 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GJB7 RNA expression–survival associations across cancer types. High GJB7 expression shows unfavorable associations in COAD and THCA, but favorable associations in READ, SCLC, LUSC and UCS. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify READ as the clearest survival context for GJB7 RNA expression.
This table summarizes GJB7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for GJB7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GJB7 shows lower tumor expression in THCA and KIRP and higher tumor expression in BLCA, HNSC, LUSC and STAD. The BLCA box plot shows higher GJB7 RNA expression in tumor versus normal tissue (log2 FC = +2.117, t-test p < 0.001).
This table shows molecular features associated with GJB7 in patient tissues and cancer cell lines. In patient samples, GJB7 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GJB7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
